WARRANTS IN STAYBLE THERAPEUTICS
In connection with the listing on Nasdaq First North during Q1 2020 a unit issue was carried out which included warrants of series TO1. Each warrant entitles to subscribe for a new share in the Company during the period from and including 17 November to and including 1 December 2020.Read more about the Warrant
Latest press releases
The Subscription Period for the Warrants of Series TO1 in Stayble Therapeutics AB begins Today October 17, 2020
Today is the first day of exercise TO1 for subsription to company shares that extend to December 1, 2020. Every one warrent gives the right to subscribe one new share in the Company to an exercise pri...
The Exercise Price for the Warrants of Series TO1 in Stayble Therapeutics AB has been set to SEK 12,30
Stayble Theraputics AB carried out during the first quarter of 2020 in conection with the listing on Nasdaq First North Growt Market, an issue of units where one unit consisted of one newly issued sha...
Bridging the therapeutic gap
About 30% of all patients with discogenic cLBP are helped by therapy such as analgesics and physiotherapy, and only 1% undergo spine surgery. Stayble’s product STA363 will bridge the gap between conservative and radical therapy to the benefit of millions of patients presently left on their own to cope with sustained and disabling pain.Our market
Treating the root cause of the disease. Not just the symptoms.
Instead of costly or time-consuming procedures, such as spinal fusion or long-term physiotherapy, our cLBP treatment is an easily performed, single injection procedure that stabilises the disc by transforming it to connective tissue. Unlike any other currently available treatment, this has the potential to permanently attenuate the pain significantly faster than surgical intervention.
An intervertebral disc consists of two main parts: the disc centre and the wall. The disc centre consists largely of a highly hydrated gel together with nucleus pulposus cells and fibroblasts.
DEGENERATED UNTREATED DISC
When a disc degenerates it becomes less stable and proinflammatory substances formed during the degenerative process can leak from the inner core of the disc. Pain-sensing nerves within and outside the wall of the disc are activated. These processes cause back pain.
By injecting STA363 directly into the degenerated intervertebral disc, the cells are triggered to produce collagen and the damaged disc is transformed into connective tissue. This helps restabilise the intervertebral segment and reduces leakage of proinflammatory substances.
Get in touch
We are always looking for passionate people who are interested in joining us to help realizing our vision. Please leave your contact details and we will get back to you email@example.com